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Abstract 
Alzheimer’s disease (AD) is an age related progressive neurodegenerative disease. The exact mechanisms 
that lead to cell death are not entirely understood. It has been shown that accumulation of amyloid-beta-42 
(Aβ42) plaques generated by mis-cleavage of amyloid-precursor-protein is the cause of neurodegeneration 
seen in AD.  This is due to the hydrophobic nature of Aβ42 due to extra two amino acids added to the typical 
and naturally occurring Aβ40 in the body. These Aβ42 plaques trigger neuronal death because of the toxic 
nature and stress they exert on the neurons. In this study, Drosophila melanogaster transgenic model where 
human Aβ42 coding cDNA is ectopically expressed in the developing fly retina comprising of retinal neurons 
to study the effect of ultrasound waves. Our hypothesis is to employ ultrasound wave exposure as a possible 
treatment to Alzheimer’s Disease. Ultrasound is a high frequency and lower energy sound wave, which may 
have less deleterious effect on cells in the tissue. In theory, using energy emitted from these waves would 
break down the plaques limiting damage due to degeneration. The wild type will be used as a control to see 
any side effects of the ultrasound treatment, while an AD affected fly will be used to determine effectiveness 
of the treatments. The goal of this project is to standardize the optimum ultrasound treatment, to observe the 
effects on survival rates, prevent neurodegeneration by removing or decreasing plaque damage.  By varying 
the height, medium, time, and number of treatments, the survival rate and rescue can be tracked. Further 
studies using larval imaging approach can be used to see early stage effects of the ultrasound. These studies 
will allow testing the efficacy of commonly used treatment in sports related tissue injuries to cure 
inflammation and also to dislodge protein aggregations in Alzheimer’s disease where accumulation of Aβ42 
plaques is the hallmark. 
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As per Drosophila nomenclature, gene names and symbols are italicized and after first time the 
names of the genes are abbreviated while protein names and symbols are written in uppercase letters 
(http://flybase.org/static_pages/docs/nomenclature/nomenclature3.html#1)  
Background  
 
 Alzheimer’s disease (hereafter AD) is a progressive neurodegenerative disease that 
has no cure to date (Shriver et al., 2011; Sarkar et al., 2016; Alzheimer’s Association). It 
is the 6th leading cause of death in the United States affecting every 1 in 3 people ages 65 
and older (Shriver et al., 2011; Sarkar et al., 2016; Alzheimer’s Association). Every 66 
seconds someone in the United States is diagnosed with Alzheimer’s (Alzheimer’s 
Association).  It is estimated that by 2050, more than 16 million people worldwide will be 
living with Alzheimer’s disease (AHAF, 2012).  This statistic is due to a few different 
changing variables. One is that people are dying of less acute illness and are therefore living 
longer. AD is an age related disease and as the “baby boomer” population grows older, 
many more people will get diagnosed with Alzheimer’s. Another factor is the awareness 
of the disease and its accompanying symptoms.  
 
History of Alzheimer’s Disease  
 
AD symptomatic characterization is decline in cognitive and behavioral functions 
eventually leading to the death of the patient. Before 1906, there was not a formal 
diagnosis. However when writings from the past are examined, there are similar symptoms 
found. For example, in Egypt and Rome in ninth century B.C. and 200 AD respectively, 
there were texts describing Alzheimer’s. In England, there were verbal tests for 
forgetfulness (Plontz, 2011).  
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In the 20th century, a formal diagnosis was associated with the symptoms we now use 
for diagnosis. The first patient to be diagnosed with Alzheimer’s disease was a 52 year old 
female named Frau Auguste D, who exhibited memory loss and difficulty in talking and 
comprehension. She was followed for many years before passing away. The doctors who 
followed her case reported that she could correctly identify objects from daily life such as 
pens or purses but when asked who her husband was, she was unable to comprehend the 
question or that she had a husband (Graeber, 1997).She exhibited the classic signs of 
memory loss and difficulty in speech and comprehension. Post-mortem, her brain was 
autopsied where Dr. Alois Alzheimer and Dr. Emil Kraeplin found plaques and tangles 
(Shriver et al, 2011; Plontz, 2011). These plaques served as the classic identifiers of this 
disease but could be diagnosed only in post mortem tissue.  
 
Alzheimer’s Disease Symptoms 
 
      Alzheimer’s is an age related progressive disease meaning that as the patient affected 
with Alzheimer’s gets older, the symptoms get worse. “In its early stages, memory loss is 
mild, but with late-stages Alzheimer's, individuals lose the ability to carry on a 
conversation and respond to their environment” (Alzheimer’s Association). This is due to 
the continual accumulation of the Aβ42 plaques leading to neuronal death and 
neurodegeneration. This neurodegeneration leads to the expression of symptoms such as 
memory loss, cognition problems, and difficulty in speech.   
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These symptoms become more severe the longer the person lives with the disease. 
Alzheimer’s is the most common form of dementia accounting for 50 to 80 percent of the 
reported dementia cases. Dementia is a general term for when memory loss and cognitive 
abilities are impaired to the point where they interfere in daily life (Alzheimer’s 
Association). Diagnosis is made through clinical and familial experience with short-term 
memory loss. This can be something as simple as family member’s names.  People with 
Alzheimer’s have varying lifespans once a diagnosis is made. In severe cases, it may be as 
little as one year. In less severe cases some have lived as long as 25 years after with the 
average falling somewhere in between around 8 to 10 years (Wang et al, 2008). Most 
patients suffer other system complications such as infection, pneumonia, heart failure, or 
malnutrition. People with more progressed Alzheimer’s need more supervision and care. 
This combined with the duration of the disease, it can put a lot of strain on the caregivers, 
emotionally and financially.  
 
Research Efforts on Alzheimer’s Disease 
 
There has been a recent increase in AD related research due to the large number of people 
developing this disease as well as the socio-economic impact. In the United States alone, 
treatment for Alzheimer’s totals about $300 billion per year with out of pocket costs for 
the family of a single patient being around $56,000 per year (Alzheimer’s Association).  
This staggering amount of money doesn’t even provide a cure, only treatment of symptoms 
for improving the quality of life of the patients. With the “baby boomers” beginning to 
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develop the symptoms of Alzheimer’s, it is very important for continued efforts to find a 
cure and minimize the costs of treatment (Shriver et al, 2011).  
 
Clinical Regimen for Alzheimer’s Disease 
 
Currently, there are only medications that can help alleviate the symptoms. The FDA has 
approved 5 drugs for treatment. These help increase communication within the brain. These 
drugs however only mask the symptoms but do not treat the underlying cause of 
Alzheimer’s disease (Alzheimer’s Association). Due to the decreased cognition and 
memory, many people suffering from AD need increased care. This helps them to 
remember to take medications, help maintain a safe living environment, proper nutrition, 
and exercise (MayoClinic, 2015). Presently, there is a drug regimen that is administered to 
patients, which is mainly directed towards improving the quality of life. The problem is 
that AD disease is detected at a later stage when the damage to neurons is high and it is 
irreversible due to post-mitotic nature of these cells. 
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Present Scenario of AD 
 
 
Despite the increase of research, the actual cause of Alzheimer’s is still unknown. 
However there are many factors that are believed to trigger the onset of Alzheimer’s. This 
includes amyloid plaques, neurofibrillary tangles, neuronal loss, oxidative stress due to 
Reactive Oxygen Species (ROS), and genetic basis of Apolipoprotein E (ApoE). The main 
Figure 1: The Mechanism of Plaque Formation in Alzheimer’s Disease. One of the 
main causes of Alzheimer’s is the mis-cleavage by gamma secretase of the Amyloid 
Precursor Protein (APP), a transmembrane protein. This mis-cleavage results in an extra 
2 amino acids on the protein resulting in a hydrophobic nature. These hydrophobic Aβ42 
accumulate into plaques. The plaques lead to neurodegeneration [Alzheimer’s 
Association]. (Image from http://www.nia.nih.gov/alzheimers/publication/part-2-what-
happens-brainad/hallmarks-ad).  
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focus of my honors thesis research deals with amyloid plaques mediated neurodegeneration 
seen in AD. These plaques occur due to improper cleavage of a protein that forms from 
Amyloid Precursor Protein (APP). Typically amyloid-β-40 (Aβ40) is 40 amino acids long 
and is used in the nervous system so that neurons can communicate in the body (Hardy, 
2009, O’Brien, 2010, Hirth, 2010, Crews, 2010). In Alzheimer’s however, APP is 
improperly cleaved. Instead of being 40 amino acids long, it is cleaved with two additional 
amino acids making it 42 amino acids long (Aβ42) (Moran et al, 2013; Iijima,et al 2010; 
Lu, 2009; Tare et al, 2011). The addition of the two amino acids makes the protein 
hydrophobic in nature. The hydrophobic nature of the protein causes the proteins to 
aggregate to increase stability of the quaternary structure as well as increase the free energy 
of the surrounding fluid. The amyloid hypothesis suggests that accumulation of Aβ42 
hinders basic cellular processes. Some of this is due to oxidative stress, mis-regulation of 
intracellular calcium, and ER stress (Casas-Tinto et al, 2011), which results in the death of 
neurons (Hirth, 2010). This is likely due to the progressive loss of neurons in the 
hippocampus and cortex (O’Brien et al, 2010). 
 
The plaques are so detrimental because the human body cannot breakdown Aβ42 nor 
utilize this protein. When the plaques build up, the neurons can no longer communicate 
and die. The neuronal death is profound that the patient’s brain physically shrinks to about 
2/3rd the size of the typical human brain [Bier, 2005]. The focus of this project is to test 
ultrasound wave treatment to prevent the damage from the accumulation of the amyloid-
beta (Aβ42) peptide.  
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Animal Models of AD 
 
Due to the fact that the genetic and cell biological pathways are similar from insects to 
humans, several animal models have been employed to model AD. The mouse model is a 
widely employed model organism due to their close genetic and physiological similarities 
to humans. The mouse model is specifically useful for studying immune, endocrine, 
nervous, cardiovascular, skeletal and other complex physiological systems and diseases 
(NHGRI, 2016). Mouse models are similar to fly models in that they are low cost and quick 
reproductive cycle. Both can be used in experiments where a gene of interest (usually one 
that is encountered in humans) is altered and monitored for a resulting phenotype (Shulman 
et al, 2003; NHGRI, 2017, Emilien, 2004; Iijima, et al, 2004).  
 
Drosophila: An Animal Model for AD 
 
The fruit fly (Drosophila melanogaster) has been a model organism for human diseases 
for many years (Shulman et al, 2003; Emilien et al, 2004; Ijima et al, 2004; Tare et al, 
2011). It has been shownthat around 70% of human disease genes are conserved in flies 
(Bier, 2005). This makes the fruit fly a useful model for studying AD.  In addition to the 
conserved genes, Drosophila melanogaster is used to model neurodegenerative disease 
because of their genome has been completely sequenced and have a short life cycle (Bier, 
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2005).  The life cycle of Drosophila melanogaster is about 12 days from egg laying to the 
reproducing adult. The life cycle of Drosophila melanogaster has 6 main stages. After 
fertilization, the embryo develops into a first instar larvae in about 24 hours. It takes another 
24 hours for the first instar larvae to transition into the second instar. Following another 24 
hours, the second instar transitions into the third instar. Next, this third instar larvae 
metamorphoses into pupa in around 3 days. 3-5 days later, the adult fly emerges from the 
pupal case. [Drosophila melanogaster, 2017]. 
  
 
 
Figure 2: Life Cycle of Drosophila melanogaster.  The life cycle of 
Drosophila melanogaster has 6 main stages. After fertilization, an embryo 
develops in about 24 hours into a first instar larvae. After another 24 hours, the 
first instar larvae transitions into the second instar. After another 24 hours, the 
second instar transitions into the third instar. This third instar larvae 
metamorphoses into pupa in around 3 days. 3-5 days later, the adult fly emerges 
from the pupal case. This whole life cycle takes about 12 days to complete. 
[Drosophila melanogaster, 2017].  
(Image from http://www.easternct.edu/~adams/Drosophilalifecycle.html).  
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Drosophila eye as disease model system  
 
The Drosophila eye (Figure 4) is an ideal organ system to assay the effect of 
neurodegeneration as the genes involved in eye development exhibit structural and 
functional similarities between insects and humans, and it is not essential for the viability 
or fertility of the fly (Fortini et al, 2000; Pandey et al, 2011; Rincon-Limas et al, 2012; 
Singh et al, 2012). Drosophila has a fully functional nervous system with an architecture 
that separates specialized functions such as vision, olfaction, learning and memory. Disease 
models in Drosophila exploit the power of its genetics (Pandey et al, 2011; Rincon-Limas 
et al, 2012; Bier et al, 2005; Prussing et al, 2013; Tare et al, 2011) its amenability to a 
variety of mutagenesis techniques, and its ability to express foreign genes to mimic several 
important neurodegenerative disorders in the compound eye (Fortini et al, 2000; Bonini et 
al, 2003; Hirth, 2010) In addition, Drosophila is amenable to chemical screens – thus 
allowing a quick and relatively cheap whole-animal model for testing inhibitors of the AD 
neurodegeneration phenotype (Gladstone et al, 2010; Gonsalves et al, 2011).  
 
However, despite much data that is available from modeling AD in animal models such 
as the mouse and the fruit fly, the exact mechanism that causes Aβ42-dependent cell death 
has yet to be determined. Using the Gal4/UAS system on Drosophila melanogaster (Brand 
and Perrimon, 1993), we have developed an AD model with transgenic flies (Tare et al, 
2011) that mis-expresses high levels of Aβ42 in the fly retina using a Glass Multiple Repeat 
(GMR) driver. GMR is a tissue specific enhancer that is expressed in the photoreceptors of 
the fly (Moses, 1991). When the DNA binding protein, Gal4 binds to UAS, the gene of 
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interest downstream is transcribed. We then can see the gene of interested expressed in the 
fly retina due to GMR. GMR is expressed beginning in the third instar larval stage and 
onward. In our cause, we have expressed human Aβ42 which is the human gene for 
Alzheimer’s in the fly retina. Thus, our study focuses on third instar larvae, pupae, and 
adult flies to phenotypically identify neurodegeneration.  
 
 
These flies exhibit progressive neurodegenerative phenotype in the retina similar to 
that in humans. It also produces a phenotype that when compared to the wild type adult 
eye and the larval eye imaginal disc showed a reduced eye size with disorganized 
ommatidia and bristles (Finelli, 2004).  The adult Drosophila melanogaster eye develops 
Figure 3: GAL4/UAS system for Tissue Specific Expression of Gene of Interest 
(Aβ42) in Drosophila Melanogaster eye. Glass Multiple Repeater (GMR) is a tissue 
specific enhancer that is expressed in the photoreceptors of the fly retina. When the 
DNA binding protein, GAL4 binds to UAS, the gene of interest downstream is 
transcribed in the domain that is targeted. In our case, due to GMR we will see the mis-
expression of Human Aβ42, Human Alzheimer’s, in the fly retina. (Provided by Dr. 
Amit Singh). 
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from an epithetical bi-layer structure housed inside the larvae called the eye-antennal 
imaginal disc giving rise to the eye, antenna, and head cuticle of the adult fly (Kumar, 
2010). The imaginal discs of larvae develop into the pupal retina and then into the adult 
eye (Figure 4 A and B). When the plaques accumulate, the cell death is then able to be seen 
in the phenotype of the fly eye (Figure 4 C and D).   
 
 
Figure 4: A: Wild Type adult eye. B: Wild Type imaginal disc. C: GMR>Aβ42 
adult eye. D: GMR>Aβ42 imaginal disc. Neurodegeneration can be seen from the 
Wild Type imaginal discs and adult phenotype when compared to the GMR>Aβ42 
[Cutler et al, 2015].  
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The AD phenotype can be readily seen through significant change in the adult eye 
structure (size, color, necrotic spots), as well as larval imaginal discs and pupal retinas. 
This phenotype is exhibited stronger when kept at 29°C (Tare et al, 2011). As is such, for 
the most complete data, the cultures are maintained at 29°C. The adults however are kept 
at 25°C which is the most suitable for adult lifespan and reproduction. These adults of 
transgenic flies (GMR>Aβ42) exhibit strong neurodegeneration phenotype (Figure 4C). 
Similarly, in earlier stages of larval eye development, these transgenic flies eye progenitor 
tissue, viz., eye imaginal disc exhibits neurodegeneration (Figure 4D) (Cohen, 1993). 
Interestingly, earlier phenotype in larval stages are weak which worsens with time as seen  
in adult.  Thus our fly model (Figure 5) exhibits AD like neuropathology of progressive 
neurodegeneration (getting stronger with age). 
Figure 5: Drosophila eye model of Alzheimer’s Disease phenocopies its progressive 
neurodegenerative disease.  As the fly progresses developmentally, the GMR>Aβ42 fly 
(middle row) shows neurodegeneration that gets worse with time. From the imaginal discs 
and pupal retina, disorganization of the ommatidia and photoreceptors can be seen in the 
developing eye. When comparing both the Wild Type and GMR>Aβ42, the progressive 
neurodegeneration can easily be seen in the adult eye. (Image from Tare, et al.,2013).  
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Ultrasound: A Possible Therapeutic Approach for AD 
 
The aim of this project it to target Aβ42 plaques and rescue the neurodegeneration. 
Ultrasound has been used in many medical applications including but not limited to: 
diagnosis of soft tissues and organs, precision location for biopsy, imaging blood flow, 
bone sonography, echocardiography, 3D images or 4D (motion), and more recently, 
promotion of healing in tissues (Raymond et al, 2008; Leinenga et al, 2015; McLeod et al, 
1992).  
 
Ultrasound is a high frequency sound wave that can permeate tissue (RSNA, 2017). 
The proposed instrument has a frequency of 4 MHz, or a wavelength of .2 mm. Based on 
data from previous testing, the rate of heating with a frequency of 3 MHz was 1.19°C/min. 
Figure 6: Can ultrasound waves dissociate amyloid plaques.  Our hypothesis is that the 
Aβ42 plaques cause neurodegeneration. By introducing the ultrasound treatment, our 
theory is that the plaques will dissociate and rescue the fly retina from Aβ42 mediated 
neurodegeneration. (Figure provided by Dr. Amit Singh) 
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There was also testing done using 1 MHz which gave a 0.13°C/min rate (Hayes et al, 2004). 
By plotting and extrapolating the data, the rate is equal to .53(MHz)-.04. Theoretically, the 
4 MHz ultrasound used in this experiment should emit 1.72°C/min. Using the knowledge 
that there is heat released as the ultrasound is used, testing can be done to determine 
effectiveness of ultrasound as an AD treatment. As the heat is released, there is energy that 
will travel through the tissues and target the Aβ42 plaques. Our hypothesis is that the 
energy emitted from the ultrasound as high frequency waves will disrupt the aggregation 
of the proteins. By breaking down the plaques, our theory is that it will prevent 
neurodegeneration.  
 
The ultrasound used in this study is a Graham-Field Grafco Pocket Doppler. This 
instrument has a 4 MHz frequency. This frequency leads to a lower energy. The instrument 
was chosen to be the middle of the line for this very reason. With a lower amount of heat, 
there is a lesser chance that there will be damage to the flies while attempting to dissociate 
the aggregated plaques. This frequency however, is still strong enough with the correct 
dosage, to cause an effect.  
 
Throughout this project, there will be various experiments to determine to best way to 
most efficiently deliver this treatment. The set up (Figure 9) will be the base to work from. 
All treatments will be given from above the larvae from the attached position on the clamp 
stand. Along the clamp stand, height can be adjusted as necessary. All trials will occur in 
the beaker, allowing testing to maintain consistency even when changing the media from 
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air to water. The time within these parameters will also be changed to identify the optimal 
timing for the greatest beneficial effect on the neurodegeneration. Immediately after 
treatment, larvae will be dissected and the eye discs will be mounted to determine efficacy 
of each treatment in relation to the transgenic flies (GMR>Aβ42), the wild type, and other 
experiments. Trials will be repeated and those treated will be allowed to hatch in an effort 
to measure efficacy of the treatment. Efficacy will be measured by survival rates as well as 
phenotypical rescue.  
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Materials and Methods 
  
 Fly stocks 
 
 All fly stocks used in this study can be found and described in Flybase 
(http://flybase.bio.indiana.edu). The fly stocks that were used in this study were 
GMRGal4>UAS-Aβ42 (GMR>Aβ42) (Tare et al., 2011) and Wild Type (Li et al, 2002).  
 
 This study used the Gal4/UAS system for targeting misexpression of Aβ42 in the 
fly retina.  All experiments used the GMR line which is expressed in the imaginal discs of 
larvae, pupal retina, and adult eye in the fly (Moses, 1991). All stocks were kept in 25℃ 
and 29 ℃. Adult flies were kept at 25℃ in which they are best suited to for lifespan and 
reproduction. Egg layings were kept at 29℃ where the misexpression of Aβ42 in the retina 
exhibits a stronger neurodegenerative phenotype (Tare et al, 2011).  
 
Immunohistochemistry 
 
 Eye-antennal imaginal discs were dissected from third instar larvae and were 
stained following the protocol (Singh et al., 2002). The dissected discs were washed in 
Phosphate Buffered Saline (PBS) and then fixed in 16% paraformaldehyde (in PBS) for 20 
minute. They then were washed with PBST three times for ten minutes each totaling 30 
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minutes. The discs were incubated overnight in primary antibodies rat anti-ELAV (1:200) 
(Developmental Studies Hybridoma Bank) and rabbit Discs-large (Dlg) (1:100).  The 
following morning, the discs were washed in PBST three times for ten minutes each 
totaling 30 minutes. The discs were then incubated with secondary antibodies for about 2 
hour. The secondary antibodies used were:  Mouse Cy3 (1:300) and Rat Cy5 (1:250) 
(Jackson Lab). After the two hours passed, the samples were then washed in PBST three 
times for ten minutes each totaling 30 minutes. The imaginal discs were then isolated from 
the accompanying structures. These prepared discs were then mounted in Vectashield. 
Immunofluorescent images were taken using the Olympus Fluoview 1000 Confocal 
Microscope. The final images were prepared using Adobe Photoshop[Bachmann et al, 
2008].  
Table of the Antibodies Used for Staining Eye-imaginal Discs. 
Antibody Used  Prepared in Concentration 
Used 
Source 
Primary Antibodies    
Elav Rat 1:200 DSHB* 
Dlg (Discs-large) Rabbit 1:100 A gift from        
K. Cho 
Secondary Antibodies    
Cy5 Rat 1:250 Jackson Lab 
Cy3 Mouse 1:300 Jackson Lab 
     *DSHB – Developmental Studies Hybridoma Bank 
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Adult Eye Imaging 
 
 Using the Axioimager.Z1 Zeiss Apotome, adult eye images were able to be taken. 
The process to do this was as follows. The adult flies were frozen and then prepped by 
removing legs and wings. Then they were mounted onto a needle. This image was taken 
by using the extended depth focus function of the Axiovision software. This is done by 
compiling the individual stacks from the Z-stack. The final images were prepared using 
Adobe Photoshop.  
 
Ultrasound Regimen 
 
  The Ultrasound treatments will be given using the Grafco Doppler. This probe 
emits a frequency of 4 MHz which is .2 mm. The probe releases 1.72℃/ min. The probe 
will be fixed in place to provide consistency throughout all trials. It will be attached through 
a clamp to a ring stand. A ruler will be attached to the ring stand in order to allow for easy 
checking before each trial. All trials will occur at 10 cm from the base. The samples will 
be placed into a 100 mL beaker to allow ample space for all samples to not be crowded 
together. All treatments will be timed using a stopwatch for accuracy and consistency. 
These times will vary depending on the study to determine an optimum time. If water is 
used, the amount of 2mL will be measured in a graduated cylinder. The water will be 
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poured over the samples after they have been placed in the beaker and under the ultrasound 
to minimize the amount of time under water. The treated samples were then placed into 
new vials of food until they hatched out and were imaged.  
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Results  
 It is an established fact that one of the reasons for onset of AD is accumulation of 
amyloid plaques outside the neurons in the central nervous system. The rationale of our 
research was to test if ultrasound waves, which are low energy waves, can dissociate the 
Aβ42 plaques. The larval imaginal disc Figure 4B develops into the adult eye Figure 4A.  
When Aβ42 is mis-expressed in the neurons of the developing eye in the GMR> Aβ42 fly, 
it results in neurodegeneration in the eye. We can see this neurodegeneration through the 
phenotype of the fly.   
  In an attempt to rescue from neurodegeneration, a variety of ultrasound regimes 
were given to trials of both wild type and GMR>Aβ42 using the setup seen in Figure 9. 
We needed a baseline to compare the survival rates to. This control can be seen in Table 2 
and 3 for Wild Type and GMR> Aβ42 respectively. Both trials were taken through the 
process that the rest of the trials did with the exception of ultrasound treatment. The purpose 
of this was to control for any factors such as trauma due to moving from food vial to 
treatment beaker to a new food vial as well as stress from being in water. The Wild Type 
had an average survival rate of 73% and the GMR>Aβ42 had an average survival rate of 
53%. These rates were then used for comparison of all other treatments and trials.  
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Ultrasound Treatment Regimen:  
 
Comparing Treatment in Water to Air 
 To begin this study, we looked at comparing the medium through which we gave 
the ultrasound treatment. We compared the survival rates of both Wild Type and GMR> 
Aβ42 when treated through only air versus water. The amount of water that was chosen 
was 2 mL.  This amount was selected to adequately cover the sample. However, too much 
water could cause drowning the flies and therefore was a factor that was considered. The 
2 mL water allowed the larvae to be surrounded in water without completely covering them 
and thus suffocating them. In Table 1 and Graph 1 the results from this experiment can be 
seen. To span a range of time for comparison, 10, 15, and 30 seconds were the times 
selected for exposure to the ultrasound waves.  From allowing the larvae of each 
experiment to hatch out, it was determine that for both Wild Type and GMR> Aβ42 the 
survival rates were higher in those that were treated in the water at all time points.  
 
Table 1: From these trials that were done on both Wild Type and GMR>Aβ42, the data 
suggests that the higher survival rates were seen in the flies that were treated in water. 
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Finding the Optimum Time Treatment 
 Next we wanted to determine an optimal amount of time for dosage. All flies were 
treated in 2 mL of water based on the results from the previous trials. For both Wild Type 
and GMR> Aβ42, the same treatment trials were used. Both were treated at 0, 10, 20, and 
30 seconds. Results for the trials of Wild Type can be seen in Table 2 and Graph 2. The 
results for GMR> Aβ42 can be seen in Table 4 and Graph 4. For the Wild Type, 10 seconds 
had a survival rate of 33% and for 20 seconds the survival rate went up to 36%. For the 
GMR> Aβ42 10 seconds had a 20% survival rate and at 20 seconds this went down to 13%. 
Due to the slight discrepancy in the survival rates of the two times, we kept and used both 
times for future trials.  
 
Table 2: These trials were done on the Wild Type, the data suggests that the higher survival 
rates were seen in the flies that were treated for 20 seconds. Those treated for 10 seconds 
were very close in terms of percent survival. Due to this and the data shown for 
GMR>Aβ42 on times, the 10 and 20 second treatment times were kept for future trails. 
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Table 3: These trials were done on the GMR>Aβ42, the data suggests that the higher 
survival rates were seen in the flies that were treated for 10 seconds. Due to the close 
survival rates in the Wild Type trials however, the 10 and 20 second treatment times were 
kept for future trails. 
  
Multiple Exposures 
 
 Following this, we wanted to see if we could increase rescue of the adult phenotype 
by administering multiple doses of ultrasound throughout the life of the developing fly. We 
started treatment at the larval stage and continued to treat once per day until the first fly 
from the batch hatched out. Trials were run for both 10 and 20 seconds to see if one would 
produce a greater result than the other.  As seen in Table 5 and Graph 5, the survival rates 
of those with multiple exposures significantly decreased. We determined that the multiple 
doses negatively impacted survival rate. From these trials, single dosage was determined 
to lead to the most effective outcome.  
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Table 4. The data collected in Tables 2 and 3, the 10 and 20 second treatments were applied 
once daily to separate trials from the larval stage to the first adult that hatched. In both Wild 
Type and GMR>Aβ42, the survival rates were much lower in the multiple trials than 
compared to the control. 
 
Comparing Treatment in Larval versus Pupal Stage 
 
Finally, we tested the difference of treating larvae in comparison to treating pupae. Again, 
treatment was given for 10 seconds or 20 seconds in 2 mL of water as a single dose. Table 
6 and Graph 6 show the results of these trials. Survival rates were slightly higher for all 
trials of Wild Type and GMR> Aβ42 at all times when the pupae were treated instead of 
the larvae.  
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Survival Rates 
 
 In addition to survival rates, imaging was taken to look at the phenotypical rescue 
to determine efficacy. In Figure 4, the Wild Type and GMR>Aβ42 adult eye and larval 
imaginal disc can be seen. The disorganization in the GMR>Aβ42 imaginal disc can be 
seen easily in comparison to that of the Wild Type. Similarly, the Wild Type adult eye in 
terms of color, shape, and size is significantly different than that of the GMR>Aβ42 adult 
Table 5: From these trials that were done on both Wild Type and GMR>Aβ42, the 
data suggests that the higher survival rates were seen in the flies that were treated in 
the pupal stage in comparison to those treated in the larval stage. Both Wild Type and 
GMR>Aβ42 were treated at either pupal or larval stage and in separate trials were 
given treatment times of either 10 or 20 seconds long. All trials occurred in 2 mL of 
water.   
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fly eye.  In Figure 7A is the Wild Type imaginal disc after immuno-histochemical staining, 
the GMR>Aβ42 imaginal disc is shown in Figure 7B, and Figure 7C is the GMR>Aβ42 
with ultrasound treatment imaginal disc. From this comparison we can see there is some 
rescues in the GMR>Aβ42 imaginal disc in terms of size and organization of the 
ommatidia.  
 
Imaging 
 
 We also imaged the adult flies from some of the trials for comparison to the Wild 
Type adult eye and GMR>Aβ42 adult eye. In Figure 8 we can see that in both pupal 
treatments and larval treatments at 10 and 20 seconds some rescue can be seen in the eye. 
The color and shape are indicative to lesser amount of damage to the neurons of the 
developing eye of the GMR>Aβ42 fly. Similarly, the imaginal discs that were stained to 
distinguish the photoreceptors in the eye of the larvae that were treated with 10 seconds of 
ultrasound in 2 mL of water (Figure 7) were imaged using the confocal. This image shows 
increased organization of the ommatidia and less holes and larger size due to less damage 
from neurodegeneration. These suggest that the treatment of ultrasound is dissociating the 
plaques and decreasing neurodegeneration.  
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Discussion  
 
 Alzheimer’s Studies 
 
Alzheimer’s is a widespread disease affecting close to 50 million people 
worldwide. It is a growing epidemic that is predicted to impact 135 million people by 2050 
(Wake up world, 2017).  From the increase prevalence of the disease, there has been more 
money and research efforts dedicated to the study of the disease, from cause to cure. Mouse 
and fly models have been used to study AD and some have also looked at using ultrasound 
as treatment. Previous studies have looked at using ultrasound waves to allow medications 
to pass thorough the blood brain barrier. Recently ultrasound has been used to dissociate 
the plaques in the brain. Studies on mice show that mice who received the treatment had 
significantly improved memory (Wake up world, 2017). Our studies look at optimizing the 
ultrasound to rescue the fly retina from neurodegeneration.  
 
Will Ultrasound Treatment work? 
 
 Our studies looked to determine if the ultrasound waves work to dissociate the 
plaques in the brain leading to neurodegeneration.  If the low energy sound waves emitted 
from the ultrasound device can break up the plaques, then rescue will be seen in the 
phenotype of the fly retina.  
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 We selected the probe for this specific frequency. By using a lower energy sound 
wave, there is less heat emitted. This calculated heat emission is 1.72℃/min. With a lower 
emission of heat, there is a lesser chance of damage to the fly internally. However, the 
probe is still emitting sound waves at a frequency that can break up the plaques.  
 
 Our preliminary data suggests that these treatments may improve the phenotype 
and indicate rescue. While we have tested various dosages and treatments, the survival 
rates are still lower than those without testing. This indicates that while there has been some 
rescue, there still might be problems with the dosage. Our studies have looked into finding 
the optimal dosage for treatments, which would optimize the amount of rescue as well as 
the survival rates.   
 
 In our studies we found that using water was better than when the larvae or pupae 
were treated in air. We had use a quantity of water to fully cover the samples but minimal 
enough that the flies in pupal or larval stages can still breathe. In previous studies there 
was some concern that the ultrasound waves may be refracting from the surface of the glass 
beaker when the samples were placed in there (Raymond et al, 2008). By adding the water, 
the signal that refracts back is dampened and diffused due to the density differences. The 
survival rates suggest that the water does in fact lessen the damage from refracting sound 
waves.  
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 Following the water study, the next study was to find the optimal timing. We 
needed to find a time that was long enough to create an effect but not so long to cause 
damage and lower the survival rate. We found by imaging the adults of those treated with 
10 seconds showed a small phenotypical rescue.  In an attempt to increase phenotypical 
rescue, we increased the dosage to 30 seconds. When we reached 30 seconds however, the 
survival rate decreased. We believe this is due to the heat that is emitted from the ultrasound 
probe. The longer the samples are subjects to the sound waves, the more heat that 
accompanies these waves. The survival rate suggest that the samples are able to handle the 
minimal amount of heat that they are exposed to during the 10-20 seconds of treatment.  
 
 Next the number of doses was considered. Keeping in mind the amount of heat 
released in a continuous dose, the thought was if we split up the heat released in intervals 
the damage would be less or removed. By spacing the treatments out by day, the samples 
temperature would be allowed to return to normal from any increases that occur during the 
treatment. However, as the results show, this is did not improve the survival rates and in 
fact did the opposite. The survival rates decreased significantly. This was believed to be 
due to a combination of stress induced from relocation for treatment as well as being 
continually subjected to heat from the sound waves.  
 
 Finally, we looked at the treating pupal versus larval stage. From testing it was 
determined that the pupal stages survived the treatment better than the larval treatment. A 
study showed that temperature significantly impacts juvenile mortality (Couret et al., 
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2014). From this study and the corresponding survival rates, it would suggest that the 
change in temperature has a greater effect on the survival rate of the larval samples. Our 
data corresponds with this conclusion while still showing a rescue in the adult retina 
through imaging.   
 
Optimum Dosage  
 
Our studies suggest that ultrasound waves can dissociate the plaques that are 
associated with the neurodegeneration in Alzheimer’s disease. This can be seen through 
the imaging of the imaginal discs as well as the adult eyes of those that have been subjected 
to treatments. While the survival rates are decrease compared to those without treatment, 
the optimal treatment dosage for maximal survival was determined.  
 
 After the various and repeated treatments, the optimum dosage was determined 
based on rescue of phenotype and survival rate. The optimum regime that our studies 
suggest have the highest survival rate would be as follows: a single treatment in 2 mL of 
water in the range of 10-20 seconds at the pupal stage of the fly’s life. By doing treatment 
as described, the ultrasound creates the least amount of damaging side effects increasing 
the viability in comparison to the other trials.  
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 This treatment was also shown through the imaging done on the adult eye to show 
some rescue. The rescue has not been a complete rescue when compared to the Wild Type 
fly. However, when the GMR> Aβ42 with treatment adult eye is compared to the GMR> 
Aβ42 without treatment, some rescue is seen. The color of the eye is closer to the wild-
type, the size of the eye is slightly bigger, and necrotic spots are not present.  
 
 While this testing does not show complete rescue, there has been some relief of the 
neurodegeneration. The larval imaginal disc of the GMR> Aβ42 with ultrasound treatment 
does show reorganization of ommatidia and a larger area of photoreceptors in comparison 
to the GMR>Aβ42 without treatment. This along with the adult images suggest that 
ultrasound can dissociate the Aβ42 plaques to an extent providing some rescue.  
 
Conclusions 
 
 From the tests we ran and described in detail above, we determined the most 
effective dosage with the highest survival rate. The optimum dosage was determined to be 
a single dose of ultrasound treatment, in water for 10-20 seconds at the pupal stage. As 
seen in the adult phenotype (Figure 8), from this treatment regimen there has been a slight 
rescue. This regimen combines treatments to improve efficacy while maintaining the 
highest survival rate.  
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Future Directions 
 
Further testing and imaging should be done on the pupal retina of the pupal flies 
that are treated to see if the confocal imagining confirms rescue. From there, the time range 
of 10 to 20 seconds can try to be narrowed down to find a more specific optimum treatment. 
These results will be looked at by examining the adult phenotype as well as the pupal retina 
images. If both the adult eye and pupal retina images of the pupas that have been treated 
with the optimum dosage show rescue, it strongly suggests that the regimen may help 
reverse or block the effects of the plaques that cause the neurodegeneration in the retina of 
the fly.   
 
Other imaging could be done on the wing discs to see if the ultrasound is damaging 
surrounding organs that could be decreasing the survival rates. If there is damage, then a 
mechanism could potentially be made to deliver the waves in a more specific manner to 
target the imaginal discs only. All of these could help find a more optimum dosage and 
potentially increase rescue in the retina of the fly. 
 
Other testing is being done on other models such as mouse model have shown 
similar promise. The studies such as Leinenga et al in 2015 showed an increase of memory 
in 75% of the mice treated. They hope to continue these studies further on sheep and if 
successful, later on humans.  
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 Data Figures 
 
 
Table 1 and Graph 1: Air versus Water: From these trials that were done on both Wild 
Type and GMR>Aβ42, the data suggests that the higher survival rates were seen in the flies 
that were treated in water. The data from Table 1 was graphed (Graph 1) for visual ease.  
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Table 2 and Graph 2: Wild Type Time Trials:  From these trials that were done on the 
Wild Type, the data suggests that the higher survival rates were seen in the flies that were 
treated for 20 seconds. Those treated for 10 seconds were very close in terms of percent 
survival. Due to this and the data shown for GMR>Aβ42 on times, the 10 and 20 second 
treatment times were kept for future trails.  The data from Table 2 was graphed (Graph 2) 
for visual ease. The top line of data from Table 2 shows the survival rate of Wild Type 
without exposure to the ultrasound but subjected to all other aspects of the treatment to 
serve as the control. 
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Table 3 and Graph 3: GMR>Aβ42 Time Trials: From these trials that were done on the 
GMR>Aβ42, the data suggests that the higher survival rates were seen in the flies that were 
treated for 10 seconds. Due to the close survival rates in the Wild Type trials however, the 
10 and 20 second treatment times were kept for future trails.  The data from Table 3 was 
graphed (Graph 3) for visual ease. The top line of data from Table 3 shows the survival 
rate of GMR>Aβ42 without exposure to the ultrasound but subjected to all other aspects 
of the treatment to serve as the control.  
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Table 4 and Graph 4: The Effect of Multiple Exposures of Ultrasound on Survival 
Rate: From the data collected in Tables 2 and 3, the 10 and 20 second treatments were 
applied once daily to separate trials from the larval stage to the first adult that hatched. In 
both Wild Type and GMR>Aβ42, the survival rates were much lower in the multiple trials 
than compared to the control. Graph 4 shows the data from Table 4 for visual ease.  
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Table 5 and Graph 5: Pupal versus Larval: From these trials that were done on both 
Wild Type and GMR>Aβ42, the data suggests that the higher survival rates were seen in 
the flies that were treated in the pupal stage in comparison to those treated in the larval 
stage. Both Wild Type and GMR>Aβ42 were treated at either pupal or larval stage and in 
separate trials were given treatment times of either 10 or 20 seconds long. All trials 
occurred in 2 mL of water.  The data from Table 5 was graphed (Graph 5) for visual ease. 
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Figure 7: Comparison of the Imaginal Discs of Wild Type, GMR>Aβ42, and GMR> 
Aβ42 with Ultrasound Treatment.  A: Wild Type larval imaging with Dlg/Elav staining 
B: GMR>A𝛽42 fly larval imaging with Dlg/Elav staining C: GMR>A𝛽42 fly larval 
imaging with Dlg/Elav staining after 10 second ultrasound treatment in 2 mL of water. 
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Figure 8: Comparison of Adult Eye Phenotypes in Wild Type, GMR>Aβ42, and 
GMR> Aβ42 with Differing Ultrasound Treatments. A: Wild type no treatment, B: 
GMR>A𝛽42 fly 10 seconds of treatment in pupal stage, C: GMR>A𝛽42 fly 20 seconds of 
treatment in pupal stage D: GMR>A𝛽42 fly no treatment, E: GMR>A𝛽42 fly 10 seconds 
of treatment in larval stage, F: GMR>A𝛽42 fly 20 seconds of treatment in larval stage. 
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Figure 9: Ultrasound set up. All treatments and trials occurred in accordance with this 
protocol. The setup is shown in figure. Samples were transferred from their food vials to 
the beaker. The Grafco Pocket Doppler emits a 4 MHz frequency and 1.72℃ per minute. 
The setup remain in the same place for all trials to remove factors that could affect the 
treatments. The height of the probe remained at 10 mm for all trails for consistency.  
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